Biotech Values

[dewophile]

even if your bullish market-share projection for Lambda should come to pass, one can question how much business there will be for interferon drugs in particular and HCV drugs in general once Telaprevir and Boceprevir cure the bulk of the already-diagnosed patient pool

that is exactly why i think the buyout was not a bad deal for zgen as some others believe (although i do think lambda would take 100% of whatever inf market there was should it make it to market)